HC Wainwright Reiterates Buy Rating for Oncternal Therapeutics (NASDAQ:ONCT)
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $19.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 106.30% from the stock’s previous close. Separately, StockNews.com began […]
More Stories
Insider Selling: Peyto Exploration & Development Corp. (TSE:PEY) Director Sells 1,070 Shares of Stock
Peyto Exploration & Development Corp. (TSE:PEY – Get Free Report) Director Stephen Jonathan Chetner sold 1,070 shares of the stock...
Insider Selling: Peyto Exploration & Development Corp. (TSE:PEY) Director Sells 1,070 Shares of Stock
Peyto Exploration & Development Corp. (TSE:PEY – Get Free Report) Director Stephen Jonathan Chetner sold 1,070 shares of the stock...
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 9,868 Shares of Stock
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 9,868 shares of the company’s stock...
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 9,868 Shares of Stock
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 9,868 shares of the company’s stock...
Marsh & McLennan Companies, Inc. (NYSE:MMC) Receives $215.81 Consensus Target Price from Analysts
Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC – Get Free Report) have earned an average recommendation of “Hold” from...
Marsh & McLennan Companies, Inc. (NYSE:MMC) Receives $215.81 Consensus Target Price from Analysts
Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC – Get Free Report) have earned an average recommendation of “Hold” from...